RxSight (NASDAQ:RXST – Get Free Report) and Embla Medical hf. (OTCMKTS:OSSFF – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.
Earnings and Valuation
This table compares RxSight and Embla Medical hf.”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| RxSight | $134.48 million | 2.03 | -$38.94 million | ($1.13) | -5.81 |
| Embla Medical hf. | N/A | N/A | N/A | N/A | N/A |
Analyst Ratings
This is a breakdown of current ratings for RxSight and Embla Medical hf., as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| RxSight | 3 | 7 | 2 | 0 | 1.92 |
| Embla Medical hf. | 0 | 0 | 0 | 0 | 0.00 |
RxSight currently has a consensus price target of $8.37, suggesting a potential upside of 27.35%. Given RxSight’s stronger consensus rating and higher possible upside, research analysts clearly believe RxSight is more favorable than Embla Medical hf..
Profitability
This table compares RxSight and Embla Medical hf.’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| RxSight | -36.80% | -17.35% | -14.70% |
| Embla Medical hf. | N/A | N/A | N/A |
Institutional & Insider Ownership
78.8% of RxSight shares are held by institutional investors. 10.1% of RxSight shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
RxSight beats Embla Medical hf. on 6 of the 9 factors compared between the two stocks.
About RxSight
RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
About Embla Medical hf.
Össur hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics, Bracing & Supports, and Patient Care. The Prosthetics segment offers mechanical products, such as lower limb prosthetics and finger prostheses; and bionic products microprocessor-controlled feet, knees, hands, liners, fingers, and other components integrated. Its Bracing & Supports segment provides bracing and supports products, such as supporting devices for spinal, hip, knee, foot, ankle, and hands for therapeutic and preventative purposes; and injury solutions for people recovering from fractures and ligament injuries. The Patient Care segment offers prosthetics for people with lower and upper limb loss or limb difference; and orthotics for neurological, gait, and musculoskeletal conditions. It serves specialized healthcare providers, including orthopedic and prosthetic clinics, hospitals, and surgery centers. The company sells its products through its direct sales networks and distributors. Össur hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Össur hf. is a subsidiary of William Demant Invest A/S.
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.
